Mineralocorticoid_NN
effector_NN
mechanism_NN
in_IN
preeclampsia_NN
._.

Mineralocorticoid_NN
effector_NN
mechanisms_NNS
were_VBD
evaluated_VBN
in_IN
29_CD
patients_NNS
with_IN
preeclampsia_NN
and_CC
in_IN
25_CD
uncomplicated_JJ
pregnancies_NNS
by_IN
measurement_NN
of_IN
plasma_NN
aldosterone_NN
,_,
levels_NNS
of_IN
mineralocorticoid_NN
receptor_NN
-LRB-_-LRB-
MR_NN
-RRB-_-RRB-
in_IN
mononuclear_JJ
leucocytes_NNS
,_,
and_CC
subtraction_NN
potential_JJ
difference_NN
-LRB-_-LRB-
SPD_NN
;_:
rectal_JJ
minus_CC
oral_JJ
values_NNS
-RRB-_-RRB-
._.

Mean_NN
values_NNS
for_IN
plasma_NN
aldosterone_NN
were_VBD
not_RB
different_JJ
between_IN
the_DT
two_CD
groups_NNS
,_,
but_CC
significant_JJ
differences_NNS
were_VBD
observed_VBN
for_IN
MR_NN
-LRB-_-LRB-
preeclampsia_NN
,_,
81_CD
+_CC
\/_CD
-_:
44_CD
receptors\/cell_NNS
;_:
controls_NNS
,_,
306_CD
+_CC
\/_CD
-_:
168_NN
-RRB-_-RRB-
and_CC
SPD_NN
-LRB-_-LRB-
preeclampsia_NN
,_,
65_CD
+_CC
\/_CD
-_:
7_CD
mV_NN
;_:
controls_NNS
,_,
12_CD
+_CC
\/_CD
-_:
5_CD
mV_NN
-RRB-_-RRB-
._.

In_IN
six_CD
cases_NNS
we_PRP
determined_VBD
MR_NN
,_,
plasma_NN
aldosterone_NN
,_,
and_CC
SPD_NN
in_IN
patients_NNS
with_IN
preeclampsia_NN
before_NN
and_CC
3_CD
months_NNS
after_IN
delivery_NN
._.

MR_NN
were_VBD
reduced_VBN
before_IN
delivery_NN
-LRB-_-LRB-
96_CD
+_CC
\/_CD
-_:
27_CD
receptors\/cell_NNS
-RRB-_-RRB-
,_,
and_CC
SPD_NN
increased_VBD
-LRB-_-LRB-
64_CD
+_CC
\/_CD
-_:
8_CD
mV_NN
-RRB-_-RRB-
,_,
with_IN
both_DT
parameters_NNS
normalizing_VBG
after_IN
delivery_NN
-LRB-_-LRB-
MR_NN
,_,
242_CD
+_CC
\/_CD
-_:
79_NN
;_:
SPD_NN
,_,
14.0_CD
+_CC
\/_CD
-_:
4_CD
mV_NN
-RRB-_-RRB-
._.

Aldosterone_NN
levels_NNS
returned_VBD
to_TO
normal_JJ
nonpregnant_JJ
values_NNS
after_IN
delivery_NN
._.

These_DT
data_NNS
suggest_VBP
an_DT
important_JJ
role_NN
for_IN
abnormalities_NNS
in_IN
mineralocorticoid_NN
effector_NN
mechanisms_NNS
in_IN
the_DT
etiology_NN
of_IN
preeclampsia_NN
and_CC
could_MD
be_VB
an_DT
useful_JJ
marker_NN
for_IN
diagnosis_NN
._.

